Chronic wounds—diabetic foot ulcers, pressure injuries, vascular insufficiency ulcers—fail to close because cellular and molecular processes that normally drive healing are disrupted.
Chronic wounds—diabetic foot ulcers, pressure injuries, vascular insufficiency ulcers—fail to close because cellular and molecular processes that normally drive healing are disrupted. Inflammation persists unchecked, angiogenesis (new blood-vessel growth) stalls, and the wound remains stuck in an early inflammatory phase, never progressing to tissue remodelling and epithelial closure. Exosomes (nano-scale vesicles secreted by cells and carrying proteins, lipids, and genetic material) have emerged as particularly promising for wound therapy because they cross-link immune signalling with fibroblast activation and growth-factor delivery. Umbilical-cord-derived fibroblasts and placental MSCs contribute direct cellular replacement of damaged dermis and subcutaneous layers. The proposed mechanism combines immunomodulation (damping excessive inflammation), stimulation of local vascular growth, and restoration of extracellular matrix architecture.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €5,000–€15,000 (dvcstem.com) |
| Main cell types studied | Exosomes, Fibroblasts from Wharton's Jelly, MSCs from Amniotic Membrane |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 59 · 7 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Chronic wound cell and exosome therapy has been subject to 59 completed trials, with 7 currently enrolling participants. Trials span diabetic foot ulcers (majority), pressure wounds, and mixed aetiology chronic wounds. Closure rates (percentage of wounds achieving full epithelial coverage) in treated cohorts typically range from 55–85% over 8–16 weeks, compared to reported historical control rates of 20–40% for advanced wounds. Exosome-based studies specifically show wound-area reduction averaging 45–70% at 12 weeks. Trial heterogeneity in wound selection, cell dose, and delivery (topical, intradermal injection, or fibrin-scaffold embedding) limits meta-analysis.
Depending on assessment, a Chronic Wounds & Ulcers protocol may draw on:
Exosome or cellular wound therapy costs €4,500–8,000 for a full treatment course (typically 2–4 applications spaced 2–4 weeks apart). Baseline imaging (photography, planimetry or 3D scanning), wound cleaning, and offtake samples add €800–1,500. Ongoing dressing costs (specialised antimicrobial or growth-factor-enriched dressings often used post-cell delivery) can reach €300–600 per week for 8–12 weeks, significantly extending total investment.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Chronic Wounds & Ulcers cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Chronic Wounds & Ulcers.
Full Chronic Wounds & Ulcers FAQ → · Chronic Wounds & Ulcers cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita